265005
地塞米松
≥99% (TLC), solid, NOS induction inhibitor, Calbiochem
别名:
地塞米松, 9α-氟-16α-甲基泼尼松龙
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H29FO5
化学文摘社编号:
分子量:
392.46
UNSPSC Code:
51422306
NACRES:
NA.77
MDL number:
产品名称
地塞米松, Most active and highly stable glucocorticoid.
SMILES string
F[C@@]21[C@H]([C@H]4[C@@]([C@@]([C@@H](C4)C)(O)C(=O)CO)(C[C@@H]2O)C)CCC3=CC(=O)C=C[C@@]31C
InChI
1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChI key
UREBDLICKHMUKA-CXSFZGCWSA-N
description
Merck USA index - 14, 2943
assay
≥99% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: 25 mg/mL
chloroform: soluble
ethanol: soluble
shipped in
ambient
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
主要靶标
rb蛋白的磷酸化
rb蛋白的磷酸化
产物不与ATP竞争。
可逆：否
细胞渗透性：否
靶标IC50：5 nM，抑制血管内皮细胞中诱导型而非组成型一氧化氮合酶的表达
Disclaimer
毒性：致癌/致畸（D）
General description
最活跃和高度稳定的糖皮质激素。导致细胞周期蛋白A和Cdk2活性降低，并抑制成骨细胞中的G1/S转换。抑制视网膜母细胞瘤（Rb）蛋白的磷酸化。抑制血管内皮细胞中诱导型而非组成型一氧化氮合酶的表达（IC50=5 nM）。通过刺激Na+ - K+泵来增强主动脉平滑肌细胞的主动阳离子转运。诱导人胸腺细胞发生凋亡。
Other Notes
Reil, T.D., et al. 2000.J. Surg.Res.92, 108.
Smith, E., et al. 2000.J.Biol.Chem. 275, 1992.
Petit, P.X., et al. 1995.J. Cell Biol.130, 157.
Stern, N., et al. 1994.Am. J. Hypertens.7, 146.
Donis, J.A., et al. 1993.Biotechniques15, 786.
Ohoka, Y., et al. 1993.Biochem.Biophys.Res. Commun.197, 916.
Sarin, A., et al. 1993.J. Exp.Med.178, 1693.
Vandewalle, A., et al. 1993.J. Cell Physiol.156, 383.
Nieto, M.A., et al. 1992.Clin. Exp.Immunol.88, 341.
Walsh, D., and Avashia, J. 1992.Cleveland Clin. J. Med. 59, 505.
Warters, R.L.1992.Cancer Res.52, 883.
Sperber, K., et al. 1991.J. Allergy Clin. Immunol.87, 490.
Radomski, M.W., et al. 1990.Proc.Natl.Acad.Sci. USA 87, 10043.
Bettger, W.J., et al. 1981.Proc.Natl.Acad.Sci. USA78, 5588.
Smith, E., et al. 2000.J.Biol.Chem. 275, 1992.
Petit, P.X., et al. 1995.J. Cell Biol.130, 157.
Stern, N., et al. 1994.Am. J. Hypertens.7, 146.
Donis, J.A., et al. 1993.Biotechniques15, 786.
Ohoka, Y., et al. 1993.Biochem.Biophys.Res. Commun.197, 916.
Sarin, A., et al. 1993.J. Exp.Med.178, 1693.
Vandewalle, A., et al. 1993.J. Cell Physiol.156, 383.
Nieto, M.A., et al. 1992.Clin. Exp.Immunol.88, 341.
Walsh, D., and Avashia, J. 1992.Cleveland Clin. J. Med. 59, 505.
Warters, R.L.1992.Cancer Res.52, 883.
Sperber, K., et al. 1991.J. Allergy Clin. Immunol.87, 490.
Radomski, M.W., et al. 1990.Proc.Natl.Acad.Sci. USA 87, 10043.
Bettger, W.J., et al. 1981.Proc.Natl.Acad.Sci. USA78, 5588.
Preparation Note
复溶后，等分并冷冻保存（-20°C）。储备溶液在-20°C下可稳定保存2个月。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Arif Yurdagul et al.
Cell metabolism, 31(3), 518-533 (2020-02-01)
Continual efferocytic clearance of apoptotic cells (ACs) by macrophages prevents necrosis and promotes injury resolution. How continual efferocytosis is promoted is not clear. Here, we show that the process is optimized by linking the metabolism of engulfed cargo from initial
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持